Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline in AstraZeneca PLC Lawsuit

January 09, 2025
AstraZeneca PLC (NASDAQ: AZN) recently faced a class action lawsuit, and The Gross Law Firm is reminding shareholders about an upcoming lead plaintiff deadline of February 21, 2025. The lawsuit alleges that the company made false and misleading statements regarding the effectiveness and safety of one of its drugs. Shareholders who suffered losses are encouraged to join the lawsuit. While this legal battle puts uncertainty on the company, it is important to note that professional stock analysts from Stocks Prognosis have recommended purchasing their stock as they foresee positive movement in the near future.
If you want to leave a comment, then you need Login or Register





Other data for AZN

Related data

AZNJune 26, 2025AstraZeneca's New Phase I Study on AZD5492: What Investors Need to Know  ~1 min.

AstraZeneca PLC has recently announced positive results from a Phase I study on its new drug candidate, AZD5492....

AZNMarch 20, 2025AstraZeneca AZN: Among the Best Diabetes Stocks to Buy According to Billionaires  ~1 min.

AstraZeneca PLC (AZN) has been recognized as one of the best diabetes stocks to buy by billionaires....

AZNMarch 16, 2025AstraZeneca's Experimental Blood Pressure Drug Could Become a Blockbuster  ~2 min.

AstraZeneca PLC (NASDAQ:AZN) has recently developed an experimental drug for treating high blood pressure, which experts believe has a strong potential to become a blockbuster in the pharmaceutical market....

AZNMarch 15, 2025AstraZeneca's Experimental Blood Pressure Drug Shows Promising Results, Outperforms Broader Market  ~1 min.

AstraZeneca PLC's recent experimental blood pressure drug has shown promising results, performing significantly better than the broader market....

AZNMarch 14, 2025AstraZeneca's Imfinzi success a step towards revolutionizing cancer treatment  ~2 min.

AstraZeneca PLC (AZN) continues to make significant strides in the field of cancer treatment with its groundbreaking drug, Imfinzi....

AZNMarch 5, 2025ASTRAZENECA PLC Stock Hits Price Target Forecast with 13.63% Profit  ~1 min.

On January 28, 2025, QuantWave issued a long signal for ASTRAZENECA PLC stock when it was trading at 68.61 $....

AZNMarch 4, 2025ASTRAZENECA PLC Hits Price Target Forecast with 13.62% Profit: A Sign of QuantWave's Accuracy  ~2 min.

ASTRAZENECA PLC (AZN) recently reached the price target forecast set by QuantWave on March 4, 2025, resulting in a profit of 13.62% for investors who followed the long signal issued on February 4, 2025....

AZNFebruary 28, 2025AstraZeneca PLC AZN: A Global Pharmaceutical Giant with Promising Growth Potential  ~2 min.

AstraZeneca PLC (AZN) is a renowned multinational pharmaceutical company with a strong presence in the global market....

AZNFebruary 26, 2025AstraZeneca PLC's Groundbreaking Research Leads to Exciting Discoveries in the Field of Medicine  ~2 min.

AstraZeneca PLC, a leading pharmaceutical company, has made significant advancements in the field of medicine through its groundbreaking research....

AZNFebruary 24, 2025AstraZeneca PLC Announces Positive Results from Clinical Trial  ~2 min.

AstraZeneca PLC, a leading pharmaceutical company, announced today that its latest clinical trial for a new drug has yielded positive results....

AZNJanuary 15, 2025AstraZeneca PLC Faces Class Action Lawsuit Deadline for Stockholders: Robbins LLP Issues Reminder  ~2 min.

Robbins LLP, a global investor rights law firm, is reminding stockholders of AstraZeneca PLC (AZN) about the upcoming lead plaintiff deadline in the class action lawsuit against the company....

AZNJanuary 23, 2025Robbins LLP Encourages AZN Shareholders with Large Losses to Seek Counsel in the AstraZeneca PLC Class Action  ~2 min.

AstraZeneca PLC, a globally renowned pharmaceutical company, is facing a potential setback as Robbins LLP, a leading shareholder rights litigation firm, encourages AZN shareholders with significant losses to seek legal counsel in the AstraZeneca PLC class action. The class action alleges that AstraZeneca PLC made false and misleading statements regarding the efficacy and safety of its COVID-19 vac...

AZNJanuary 25, 2025AstraZeneca PLC Faces Class Action Lawsuit for Investor Recovery  ~2 min.

Robbins LLP, a leading investor rights law firm, is encouraging shareholders of AstraZeneca PLC (AZN) who have suffered significant financial losses to seek legal counsel in the ongoing class action lawsuit against the company. The lawsuit, filed by Levi Korsinsky, aims to recover damages for investors who suffered losses due to alleged misleading statements and omissions made by AstraZeneca regar...

VJanuary 8, 2025Visa Inc. Faces Securities Class Action Lawsuit: Investors Urged to Seek Legal Counsel  ~1 min.

Investors in Visa Inc. (V) are advised to secure legal counsel as the company faces a securities class action lawsuit....

AZNJanuary 26, 2025Class Action Filed Against AstraZeneca PLC AZN Seeking Recovery for Investors  ~1 min.

Robbins LLP Encourages AZN Shareholders with Large Losses to Seek Counsel in the AstraZeneca PLC Class Action....